Thermo Fisher Scientific Inc. (NYSE:TMO) will release its third quarter earnings report before the opening bell on Wednesday, Oct. 21.
Analysts expect the Waltham, Massachusetts-based company to report quarterly earnings of $6.40 per share, up from $5.79 per share in the year-ago period. The consensus estimate for TMO’s quarterly revenue is $11.93 billion. It reported $11.12 billion last year, according to Benzinga Pro.
On Oct. 6, Quantum BioPharma Ltd. (NASDAQ:QNTM) said it is partnering with the clinical research division of Thermo Fisher Scientific to launch a Phase 2 clinical trial for its multiple sclerosis treatment, Lucid-MS.
Shares of Thermo Fisher Scientific fell 1.5% to close at $679.38 on Monday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- Morgan Stanley analyst Tejas Savant maintained an Overweight rating and increased the price target from $650 to $730 on Oct. 13, 2026. This analyst has an accuracy rate of 59%.
- TD Cowen analyst Dan Brennan maintained a Buy rating and boosted the price target from $675 to $760 on Oct. 13, 2026. This analyst has an accuracy rate of 72%.
- Barclays analyst Luke Sergott maintained an Overweight rating and raised the price target from $650 to $750 on Oct. 7, 2026. This analyst has an accuracy rate of 69%.
- UBS analyst Doug Schenkel upgraded the stock from Neutral to Buy and boosted the price target from $540 to $730 on Sept. 9, 2026. This analyst has an accuracy rate of 74%.
- CLSA analyst Michael Luo initiated coverage on the stock with an Outperform rating and a price target of $748 on Sept. 3, 2026. This analyst has an accuracy rate of 70%.
Considering buying TMO stock? Here’s what analysts think:
Photo via Shutterstock
Recent Comments